Loading...
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Small-molecule inhibitors of kinases involved in B-cell receptor signaling are an important advance in managing lymphoid malignancies. Entospletinib (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase. This multicenter, phase 2 study enrolled subjects with relapsed or refractory chro...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401348/ https://ncbi.nlm.nih.gov/pubmed/25696919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-08-595934 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|